J1302 Injection, sutimlimab-jome, 10 milligrams
Also known as: Fabhalta, sutimlimab
Sutimlimab-jome injection supplied in 10 milligram units, a complement component 1s inhibitor for cold agglutinin disease.
In Plain Language
Medicine for rare blood disease
Clinical Context
Used for treatment of cold agglutinin disease with inhibition of classical complement pathway activation.
RVU Information
CPT J1302 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J1302?
CPT J1302 (Injection, sutimlimab-jome, 10 milligrams) is a J Codes (Drugs) code. Sutimlimab-jome injection supplied in 10 milligram units, a complement component 1s inhibitor for cold agglutinin disease.
How is J1302 administered?
CPT J1302 is administered by a healthcare provider, typically via injection or infusion. Used for treatment of cold agglutinin disease with inhibition of classical complement pathway activation. It is used by Hematology, Internal Medicine, Transfusion Medicine.
When is CPT J1302 used?
Used for treatment of cold agglutinin disease with inhibition of classical complement pathway activation.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.